Human FCRL3/FcRH3 Antibody Summary
Accession # NP_443171
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Detection of FCRL3/FcRH3 in Human Blood Lymphocytes by Flow Cytometry. Human peripheral blood lymphocytes were stained with Goat Anti-Human FCRL3/FcRH3 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF3126) followed by Allophycocyanin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0108) and Mouse Anti-Human NKp46/NCR1 Phycoerythrin-conjugated Monoclonal Antibody (Catalog # FAB1850P). Quadrant markers were set based on control antibody staining (Catalog # AB-108-C).
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
FCRL3 (Fc Receptor-Like 3), also known as FcRH3, IRTA3, and SPAP2, is a 110 kDa molecule with sequence homology to classical Fc receptors. The type 1 transmembrane FCRL proteins contain from three to nine immunoglobulin-like domains. They are differentially expressed within the B cell lineage and can either promote or inhibit B cell proliferation and activation (1). Mature human FCRL3 consists of a 556 amino acid (aa) extracellular domain (ECD) with six Ig-like domains, a 21 aa transmembrane segment, and a 140 aa cytoplasmic domain with four immunotyrosine inhibitory motifs (ITIMs) (2 - 4). Within the ECD, human and mouse FCRL3 share 35% aa sequence identity. Alternate splicing generates several additional isoforms with deletions or substitutions in both the extracellular and intracellular regions. These include potentially secreted forms that are truncated following the second Ig-like domain (4). FCRL3 is expressed in secondary lymphoid organs on the surface of mature naïve and memory B cells, NK cells, and B cell lines derived from chronic lymphocytic leukemias (2, 3, 5). It is upregulated on B cells following LPS or anti-CD40 stimulation (6). A polymorphism in the FCRL3 promoter induces enhanced transcription and is associated with the development of autoimmune disorders in a Japanese population (6, 7). Tyrosine phosphorylation within the ITIMs of FCRL3 enables its association with SHP-1 (4).
- Davis, R.S. (2007) Annu. Rev. Immunol. 25:525.
- Miller, I. et al. (2002) Blood, 99:2662.
- Davis, R.S. et al. (2001) Proc. Natl. Acad. Sci. 98:9772.
- Xu, M.-J. et al. (2002) Biochem. Biophys. Res. Commun. 293:1037.
- Polson, A.G. et al. (2006) Int. Immunol. 18:1363.
- Kochi, Y. et al. (2005) Nat. Genet. 37:478.
- Chistiakov, D.A. and A.P. Chistiakov (2007) Hum. Immunol. 68:375.
No product specific FAQs exist for this product, however you mayView all Antibody FAQs
Reviews for Human FCRL3/FcRH3 Antibody
There are currently no reviews for this product. Be the first to review Human FCRL3/FcRH3 Antibody and earn rewards!
Have you used Human FCRL3/FcRH3 Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image